NEW YORK – ChromaCode this week debuted a new multiplexed qPCR panel to detect multi-drug resistant infections, expanding the firm's menu, which also includes a product for tick-borne pathogens launched last year that was the subject of a recent clinical study showing high accuracy.
The ChromaCode MDR panel detects genetic signatures of resistance to specific antibiotics in pathogens that are commonly thought of as hospital acquired, and is designed to be used as a screening test for infection control and isolation of asymptomatic carriers.